Some studies have consistently suggested a synergistic effect of a combination of PD-1/PD-L1 inhibitors with EGFR-TKIs in EGFR-mutated NSCLC with PD-L1 overexpression [72,73]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.